Interview with Juergen Knackmuss, Chairman, GPHF
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
Address: Rotlintstraße 75
60389 Frankfurt
Tel: 069 – 46939-662
Web: http://www.gphf.org/web/en
The Global Pharma Health Fund (GPHF) is a charitable organization initiated and funded exclusively by donations from Merck Darmstadt • Germany.Within international development assistance initiatives, the GPHF aims to improve health care and medicines supply. It currently supports the fight against counterfeit and substandard quality medicines proliferation using GPHF-Minilab® test kits.
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
The latest from German pharma, including Bayer’s 2021 financial results, the country’s plan to spend $3.14 billion on vaccine capacity to cover Covid-19 outbreaks until 2029, and Boehringer Ingleheim’s case…
A roundup of the latest news from European biotech, including BioNTech and CureVac’s German vaccine manufacturing deal; the revival of Valneva’s plans to manufacture its vaccine in Scotland; and Morphosys’…
At the recent FT webinar, ‘Supporting Pharma Innovation in Europe’, high-level representatives from Roche, Bayer, and the European Commission weighed in on how European pharma’s competitive position on innovation is…
Building on points developed in his 2020 PharmaBoardroom interview, Professor Nicolaus Kröger of the European Society for Blood and Marrow Transplantation (EBMT) outlines the progress made by the multi-stakeholder GoCART…
In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global…
Christian Conrad outlines his role as patient engagement lead for Novartis Oncology in Germany, how individual patient interactions differ from those with advocacy groups, and the current situation for cancer…
After a challenging 2020, and with more hurdles in sight, Bayer has been on an investment spree with a USD 2 billion acquisition of a San Diego-based biotech and manufacturing…
The latest news from German pharma, including Bayer’s USD 2 billion acquisition of San Diego’s Vividion Therapeutics; Boehringer Ingelheim’s new investment in a Vienna production facility; BioNTech’s plans to inaugurate…
The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest and most developed nations are represented, other smaller countries are punching…
Writing in the August edition of DIA’s Global Forum, Sanofi R&D’s Thomas Kühler outlines the bumpy journey towards the full adoption of Health Technology Assessment (HTA) across Europe. More…
Boehringer Ingelheim’s Hubertus von Baumbach, the newly appointed president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), shares the goals of his presidency and the role of the…
The latest news from German pharma, including a new US leadership team and more COVID-related investment at Merck KGaA; the CureVac vaccine’s role in fighting COVID-19 variants; and why the…
See our Cookie Privacy Policy Here
